Although blocking the PD-1 and PD-L1 axis is an attractive target for cancer treatment, many preclinical and clinical studies have concentrated on the relationship between PD-L1 and immunosuppression, but not chemoresistance. This evidence concerns the gene PDCD1 and cancer.